Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
CDTX Stock Chart & Stats
$219.02
-$4.82(-17.85%)
At close: 4:00 PM EST
$219.02
-$4.82(-17.85%)
Day’s Range― - ―
52-Week Range$15.22 - $219.64
Previous CloseN/A
Volume155.01K
Average Volume (3M)1.62M
Market Cap
$6.89B
Enterprise Value$2.15B
Total Cash (Recent Filing)$293.65M
Total Debt (Recent Filing)$1.98M
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Mar 11, 2026EPS Estimate
-1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding31,439,371
10 Day Avg. Volume3,042,349
30 Day Avg. Volume1,619,486
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.05
Price to Sales (P/S)133.87
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-47.78
Enterprise Value/Ebitda-11.32
Forecast
1Y Price Target
$209.67Price Target Upside-4.27% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-7.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsMerck announced an agreement to acquire Cidara Therapeutics in an all-cash transaction for $221.50 per share, representing a hefty 109% premium to CDTX's closing price.
Financial StrengthWith $516.9M in cash and cash equivalents, Cidara appears well-capitalized to fund operations through completion of the Phase 3 program.
Strategic AlignmentMerck has an established infectious disease business and recently purchased a respiratory biotech, indicating strategic alignment with the acquisition of CDTX.
Bears Say
Acquisition RisksThe rating is downgraded to Neutral from Buy due to potential risks such as the acquisition not being completed.
Conflict Of InterestThere might be a conflict of interest affecting the objectivity of the report, as the firm seeks to do business with the companies covered.
Rating DowngradeThe rating on CDTX shares is downgraded to Equal-weight from Overweight.
Cidara Therapeutics News
CDTX FAQ
What was Cidara Therapeutics’s price range in the past 12 months?
Cidara Therapeutics lowest stock price was $15.22 and its highest was $219.64 in the past 12 months.
What is Cidara Therapeutics’s market cap?
Cidara Therapeutics’s market cap is $6.89B.
When is Cidara Therapeutics’s upcoming earnings report date?
Cidara Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 110 days.
How were Cidara Therapeutics’s earnings last quarter?
Cidara Therapeutics released its earnings results on Nov 06, 2025. The company reported -$3.1 earnings per share for the quarter, missing the consensus estimate of -$1.337 by -$1.763.
Is Cidara Therapeutics overvalued?
According to Wall Street analysts Cidara Therapeutics’s price is currently Overvalued.
Does Cidara Therapeutics pay dividends?
Cidara Therapeutics does not currently pay dividends.
What is Cidara Therapeutics’s EPS estimate?
Cidara Therapeutics’s EPS estimate is -1.62.
How many shares outstanding does Cidara Therapeutics have?
Cidara Therapeutics has 31,439,371 shares outstanding.
What happened to Cidara Therapeutics’s price movement after its last earnings report?
Cidara Therapeutics reported an EPS of -$3.1 in its last earnings report, missing expectations of -$1.337. Following the earnings report the stock price went up 5.829%.
Which hedge fund is a major shareholder of Cidara Therapeutics?
Currently, no hedge funds are holding shares in CDTX
Cidara Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$209.67 (-4.27% Downside)
$209.67 (-4.27% Downside)
Blogger Sentiment
Bullish
CDTX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1301.27%
12-Months-Change
Fundamentals
Return on Equity
-68.70%
Trailing 12-Months
Asset Growth
219.50%
Trailing 12-Months
Company Description
Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
CDTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the development and funding of CD388, along with strong financial positioning. However, there are challenges related to manufacturing scale-up and uncertainties in flu vaccination rates and study enrollment timing.View all CDTX earnings summariesCDTX Stock 12 Month Forecast
Average Price Target
$209.67
▼(-4.27% Downside)
Technical Analysis
Catalyst Pharma
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
Ownership Overview
Currently, No data available
---